Peptide for reduction of infection and inflammation
| Reference number | |
| Coordinator | in2cure AB |
| Funding from Vinnova | SEK 2 000 000 |
| Project duration | January 2014 - February 2017 |
| Status | Completed |
Important results from the project
There is a great and unmet need for new innovative products that will reduce infection and inflammation during wounding, and in relation to use of biomaterials or medical devices. in2cure AB has developed own formulations with its proprietary TCP-25 substance, shown therapeutic effects in preclinical models, and evaluated market needs and regulatory requirements for wound healing indications.
Expected long term effects
in2cure AB has verified a product concept based on an endogenous peptide functioning via reduction of inflammation, aiding in the prevention of infection. TCP-25 has been developed as a gel formulation, and as an additive to biomaterials. Regulatory analyses, comprising stability, toxicology, and distribution have been performed. Analyses of market needs, cost-benefit, and regulatory requirements have provided in2cure with a a base towards development for selected wound healing indications.
Approach and implementation
The different parts of the project have included analyses of product effectiveness in biomaterials, development of a wound gel, cooperation with potential customers, establishment of a competent team of specialists and contract research organizations to cover necessary parts of the verification process, including regulatory affairs, business development, and intellectual property. In2cure AB has an office at the SmiLe incubator at Medicon Village and cooperates with Lund University.